Status:
UNKNOWN
Breast Cancer Women on Aromatase Inhibitors Treatment
Lead Sponsor:
Parc de Salut Mar
Collaborating Sponsors:
Instituto de Salud Carlos III
Conditions:
Osteoporosis
Osteoporosis Fracture
Eligibility:
FEMALE
40-80 years
Phase:
PHASE4
Brief Summary
The main objective of the study is to improve the life quality of women treated with AI. Cohort B-ABLE is designed to evaluate musculoskeletal events derived of using AI in breast cancer women. The pr...
Detailed Description
Postmenopausal women with breast cancer treated with aromatase inhibitors (AI) have a higher incidence of osteoporosis, fractures and other musculoskeletal symptoms, particularly pain and stiffness. B...
Eligibility Criteria
Inclusion
- Postmenopausal women with early breast cancer estrogen receptor with aromatase inhibitors treatment
Exclusion
- Previous treatment with antiresorptive treatment for osteoporosis secondary osteoporosis, as corticosteroids, Hyperparathyroidism, Kidney Chronic disease, previous treatment with aromatase inhibitors Diabetes mellitus type 1 Fibromyalgia
Key Trial Info
Start Date :
January 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT03811509
Start Date
January 1 2016
End Date
December 31 2022
Last Update
January 28 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xavier Nogues
Barcelona, Spain, 08015